中文

MicroPort® Announces Successful Non-Inferior Two-Year Clinical Data for its Firehawk Drug-eluting Stent at EuroPCR 2019

2019-05-27
Paris, France – On May 22, 2019, MicroPort Scientific Corporation ("MicroPort®, HK:0853") released the data at 24 months from its TARGET All-Comers (TARGET AC) trial. Similar to one-year primary endpoint data which has been published in The Lancet (https://doi.org/10.1016/S0140-6736(18)31649-0), the 24 months results of the TARGET AC trial demonstrated that vessels treated with Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") showed non-inferiority results when compared to vessels treated with the Xience family of drug-eluting stents. These newest clinical data were presented at EuroPCR 2019 conference held in Paris by Dr. Bo Xu, a Steering Committee member of TARGET AC trial and Director at Fu Wai Hospital, Beijing, China. This presentation will be supported by a concomitant publication in the Journal of the American College of Cardiology (JACC).
 
"The two-year follow-up of the TARGET All Comers study shows similar safety and efficacy profiles of the Firehawk® and Xience stents," said Dr. Bo Xu during his EuroPCR 2019 presentation concluding remarks, "The incidence of target lesion failure (TLF) beyond one year was low and comparable for both treatment arms, with a low rate of stent thrombosis in a broad all-comers population."
 
In the intent-to-treat population, the TLF rate's number gap between Firehawk® stent and Xience family stents is narrowed down from one year's (6.1% vs.5.9%, p=0.88) to (8.7% vs. 8.6%, p=0.92) at two year. In addition, no statistically significant differences in TLF components were observed between the two stents through two-year data between Firehawk® and Xience family stents, respectively: cardiac death (1.7 % vs. 1.1%, p=0.60), myocardial infarction (MI) related to the target vessel (5.7% vs. 5.9%, p=0.81), ischemia-driven target lesion revascularization (2.6% vs. 3.7%, p=0.21), stent thrombosis rate (ARC definite, 1.5% vs. 2.0%, p=0.99). At two years' time point, very late definite or probable stent thrombosis occurred in three patients (0.4%) in the Firehawk® group and in seven patients (0.9%) in the XIENCE group (p=0.34). Compared to one year data, the rates of myocardial infarction (MI) related to the target vessel and stent thrombosis rate (ARC definite) at two years have been flipped over. The data were also observed at 12 months post implantation for the Firehawk® stent and Xience family stents, respectively: cardiac death (1.2% vs. 0.9%, p=0.60), myocardial infarction (MI) related to the target vessel (4.5% vs. 3.9%, p=0.59), ischemia-driven target lesion revascularization (ID-TLR, 1.2% vs. 2.4%, p=0.08), and stent thrombosis rate (ARC definite, 1.3% vs. 1.3%, p=0.99).
 
"The Firehawk® stent has the lowest volume polymer and drug concentration among currently available biodegradable polymer drug-eluting stents in the world," said Dr. Ming Zheng, Vice President, Clinical Science & Medical Affairs of MicroPort®, "This is a tremendous milestone in the evolution of stent technology, and the Firehawk® stent is a next generation therapy designed to improve patient outcomes and ultimately reduce health care costs associated with the treatment of coronary artery diseases."
 

About TARGET AC study

The TARGET AC trial is a prospective, multi-center, randomized controlled clinical trial consisting of entirely European-based patients. This clinical study enrolled its first patient in December 2015 and completed enrollment of its last patient in October 2016. In total, there were 1,655 patients enrolled from 21 clinical study sites throughout Europe including countries such as the United Kingdom, France, Spain, Italy, Belgium, the Netherlands, Poland, Germany, Austria and Denmark. The trial's primary endpoint was the target lesion failure (TLF) rate at 12 months. In addition, the trial design included an Optical Coherence Tomography (OCT) sub-study consisting of 50 patients at three months post implantation and a QCA (Quantitative Coronary Angiography) sub-study consisting of 176 patients at 13 months. Patients enrolled in the TARGET AC trial will be followed for a duration of five years post implantation.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 8 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to bringing about a people-centric SuperCluster of emerging medical technologies to provide the best yet accessible ways & means to prolong and reshape lives.

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

Copyright © 1998-2018 MicroPort Scientific Corporation. All rights reserved.

CONTACT:

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6957
Email: spokesperson@microport.com

[Prev]:MicroPort® CardioFlow Attends CSI Asia-Pacific 2019

[Next]:MicroPort® Receives Reimbursement in France for Firehawk®